ASCO Annual Meeting
ASCO Annual Meeting
June 20, 2016
4 min watch
Save

VIDEO: Mogamulizumab ‘promising’ therapy for patients with rare ATL

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

A humanized monoclonal antibody directed against C-C chemokine receptor 4 effectively treated patients with adult T-cell leukemia/lymphoma when compared with standard chemotherapy, according to research Adrienne A. Phillips, MD, MPH, of Weill Cornell Medicine and NewYork-Presbyterian, presented at the ASCO Annual Meeting.

Phillips and colleagues conducted a randomized study in which patients either received mogamulizumab (Poteligeo, Kyowa Kirin Pharmaceutical Development) or a standard chemotherapy treatment of either pralatrexate (Folotyn, Spectrum Pharmaceuticals), DHAP or gemcitabine-oxaliplatin.

The response rate in patients who received mogamulizumab was 34% compared with no response in patients who received chemotherapy.

“Mogamulizumab... is promising for patients with ATL who otherwise have had no standard options [in the U.S.], Phillips said. “[Also], chemotherapy in the relapsed refractory setting is ineffective.”